{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:37:58Z","timestamp":1763707078319,"version":"3.44.0"},"reference-count":5,"publisher":"Scientific Scholar","content-domain":{"domain":["ijdvl.com"],"crossmark-restriction":true},"short-container-title":["IJDVL"],"DOI":"10.25259\/ijdvl_336_2025","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T06:55:58Z","timestamp":1758092158000},"page":"1-2","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Orelabrutinib-induced severe exfoliative dermatitis"],"prefix":"10.25259","volume":"0","author":[{"given":"Aobei","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venereology, Peking University First Hospital, Xicheng District, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangxi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Peking University First Hospital, Xicheng District, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"key":"10.25259\/IJDVL_336_2025\/ref-1","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1111\/ced.14625","article-title":"Erythroderma (exfoliative dermatitis). Part 1: underlying causes, clinical presentation, and pathogenesis","volume":"46","author":"Tso","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"10.25259\/IJDVL_336_2025\/ref-2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/0019-5154.48976","article-title":"Erythroderma: Review of a potentially life-threatening dermatosis","volume":"54","author":"Okoduwa","year":"2009","journal-title":"Indian J Dermatol"},{"key":"10.25259\/IJDVL_336_2025\/ref-3","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s40257-020-00535-x","article-title":"Dermatological toxicities of Bruton\u2019s tyrosine kinase inhibitors","volume":"21","author":"Sibaud","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"10.25259\/IJDVL_336_2025\/ref-4","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1002\/ajh.27064","article-title":"Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study","volume":"98","author":"Deng","year":"2023","journal-title":"Am J Hematol"},{"key":"10.25259\/IJDVL_336_2025\/ref-5","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s40265-021-01482-5","article-title":"Orelabrutinib: First Approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ijdvl.com\/orelabrutinib-induced-severe-exfoliative-dermatitis\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ijdvl.com\/orelabrutinib-induced-severe-exfoliative-dermatitis\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T06:56:22Z","timestamp":1758092182000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijdvl.com\/orelabrutinib-induced-severe-exfoliative-dermatitis\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,16]]},"references-count":5,"alternative-id":["10.25259\/IJDVL_336_2025"],"URL":"https:\/\/doi.org\/10.25259\/ijdvl_336_2025","relation":{},"ISSN":["0973-3922","0378-6323"],"issn-type":[{"value":"0973-3922","type":"electronic"},{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,16]]},"article-number":"1"}}